Janssen Pharmaceutical Inc.
Titusville
New Jersey
United States
569 articles with Janssen Pharmaceutical Inc.
-
J&J's Janssen terminated its integrin research collaboration with Morphic Therapeutics. This follows the June 2022 termination of a partnership with AbbVie.
-
Johnson & Johnson discontinued the Phase III trial of an investigational HIV vaccine regimen Wednesday after an independent review showed it was ineffective at preventing disease.
-
Thursday, Fate Therapeutics announced it terminated the 2020 collaboration agreement with Johnson & Johnson’s biopharma subsidiary Janssen.
-
In a comparison trial, BeiGene’s Brukinsa bested Janssen’s Imbruvica in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL).
-
Combinations including Ibrutinib stood out in hard-to-treat hematological cancers at the 64th American Society of Hematology (ASH) annual meeting.
-
New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia
12/10/2022
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new four-year follow-up results from the Phase 3 GLOW study, which showed investigational, fixed-duration treatment with IMBRUVICA® + venetoclax reduced the risk of progression or death by 79 percent among older and/or unfit patients with previously untreated chronic lymphocytic leukemia compared to patients treated with chemoimmunotherapy.
-
Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
12/10/2022
The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase 1/2 MonumenTAL-1 study of talquetamab, an investigational, off-the-shelf, bispecific T-cell engager antibody.
-
Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI™ (teclistamab-cqyv) in Combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
12/10/2022
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new results from a cohort of the Phase 1b MajesTEC-2 study of TECVAYLI™, a first-in-class, BCMAxCD3 bispecific T-cell engager antibody, in combination with DARZALEX FASPRO® and lenalidomide.
-
Setting the Stage for ASH 2022
12/9/2022
At ASH 2022, established hematology leaders like AstraZeneca, Janssen and Merck will showcase new data, and new players like Vega Therapeutics will launch new programs. -
Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
12/9/2022
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for talquetamab for the treatment of patients with relapsed or refractory multiple myeloma.
-
New TREMFYA® (guselkumab) Post-Hoc Analysis Reveals Early Efficacy Predicted Longer-Term Efficacy And Sustained Achievement Among A Diverse Active Psoriatic Arthritis Patient Population
11/11/2022
Early skin and enthesitis responses in active psoriatic arthritis patients treated with TREMFYA predicted long-term clinical response, measured at two years, including disease remission.
-
Janssen's Save Legs. Change Lives.™ is Creating a More Equitable Future for Communities at Risk of PAD-Related Amputations
11/4/2022
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the first impact summary for its Save Legs.
-
New TREMFYA® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis
10/24/2022
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data from the Phase 2b QUASAR Induction Study 1 in adults with moderately to severely active ulcerative colitis with inadequate responses to previous treatments.
-
Janssen Pharmaceutical announced data on Monday from two Ulcerative colitis (UC) trials: the UNIFI trial studying Stelara and the VEGA trial studying guselkumab and golimumab.
-
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
10/10/2022
The Janssen Pharmaceutical Companies of Johnson & Johnson announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis who received 12 weeks of combination induction therapy with guselkumab and golimumab.
-
STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis
10/10/2022
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).
-
Gene therapies developed by Janssen, Atsena, REGENXBIO and AbbVie showed promise against eye diseases this weekend at the American Academy of Ophthalmology 2022 meeting.
-
Janssen Announces Late-Breaking Data from Two Gene Therapy Programs at the American Academy of Ophthalmology 2022 Annual Meeting
10/1/2022
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the primary results from the Phase 1/2 study evaluating the investigational gene therapy botaretigene sparoparvovec in patients with the inherited retinal disease X-linked retinitis pigmentosa associated with the retinitis pigmentosa GTPase regulator gene.
-
In honor of World Cancer Research Day, Sept. 24, BioSpace spoke with Elevation Oncology, Janssen, Merck and Teclison to learn more about the latest innovations in immuno-oncology.
-
Factor XIa inhibitors developed by Bayer and the duo of BMS and Janssen Pharmaceuticals missed Phase II endpoints in data presented at ESC.